Update on acute coronary syndromes and implications for therapy

Bibliography

• MURRAY CJ, LOPEZ AD: Mortality by cause for eight regions of the world: Global Burden of Disease study. Lancet (1997) 349:1269–1276.
   PubMed Web of Science ®Google Scholar
• ARMSTRONG PW, FU Y, CHANG WC et al.: Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators. Circulation (1998) 98:1860–1868.
   PubMed Web of Science ®Google Scholar
• DAVIES MJ: A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation (1990) 82(Suppl. II):I138–1146.
   Google Scholar
• FARB A, BURKE AP, TANG AL et al.: Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation (1996) 93:1354–1363.
   Google Scholar
• COLLER BS, SCUDDER LE, BEER J et al.: Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents. Ann. NYAcad. Li. (1991) 614:193–213.
   PubMed Web of Science ®Google Scholar
• HYNES RO: Integrins: a family of cell surface receptors. Cell (1987) 48:549–554.
   PubMed Web of Science ®Google Scholar
• WAGNER CL, MASCELLI MA, NEBLOCK DS, VVEISMAN HF, COLLER BS, JORDAN RE: Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood (1996) 88:907–914.
   PubMed Web of Science ®Google Scholar
• LEFKOVITS J, PLOW E, TOPOL E: Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl. Med. (1995) 332:1553–1559.
   PubMed Web of Science ®Google Scholar
• ALMONY GT, LEFKOVITS J, TOPOL EJ: Antiplatelet and anticoagulant use after myocardial infarction. Clin. Cardiol (1996) 19:357–365.
   PubMed Web of Science ®Google Scholar
• LEWIS HD, DAVIES JW, ARCHIBALD DG et al.: Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl. I Med. (1983) 309:396–403.
   Google Scholar
• CAIRNS JA, GENT M, SINGER J et al:Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl. J. Med. (1985) 313:1369–1375.
   PubMed Web of Science ®Google Scholar
• THEROUX P, OUIMET H, McCANS J et al.: Aspirin, heparin, or both to treat acute unstable angina. N Engl. J. Med. (1988) 319:1105–1111.
   PubMed Web of Science ®Google Scholar
• THE RISC GROUP: Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet (1990) 336:827–830.
   PubMed Web of Science ®Google Scholar
• ANTIPLATELET TIZIALISTS COLLABORATION: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J. (2002) 324:71–86.
   PubMed Web of Science ®Google Scholar
• BRAUNWALD E, ANTMAN EM, BEASLEY JW et al.: ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). American College of Cardiology and the American Heart Association (2002).
   Google Scholar
• ••Excellent evidence-based guidelines for themanagement of NSTE ACS patients.
   Google Scholar
• THEROUX P, WATERS D, QIU S, Mc CANS J, DE GUISE P, JUNEAU M: Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation (1993) 88:2045–2048.
   PubMed Web of Science ®Google Scholar
• ZED PJ, TISDALE JE, BORZAK S: Low-molecular-weight heparins in the management of acute coronary syndromes. Arch. Intern. Med. (1999) 159:1849–1857.
   PubMed Web of Science ®Google Scholar
• COHEN M, DEMERS C, GURFINKEL EP et al.: A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl. J. Med. (1997) 337:447–452.
   PubMed Web of Science ®Google Scholar
• ANTMAN EM, McCABE CH, GURFINKEL EP et al.: Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) 11B trial. Circulation (1999) 100: 1593-1601.
   Google Scholar
• FERGUSON JJ, ANTMAN EA, BATES ER et al.: The use of enoxaparin and IIb/IIIa antagonists in acute coronary syndromes, including PCI: final results of the NICE 3 study [abstract]. J. Am. Coll. Cardiol (2001) 37(Suppl. A):365A (Abstract 1253–97).
   Google Scholar
• COHEN M, THEROUX P, FREY MJ et al.: Anti-thrombotic combination using tirofiban and enoxaparin: the ACUTE II study. Circulation (2000) 102 (Suppl.):11-826 (Abstract 3982).
   Google Scholar
• GOODMAN SG: The INTegrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndromes Treatment (INTERACT) trial. 51st Annual Meeting of the American College of Cardiology Atlanta, GA, USA (2002).
   Google Scholar
• MASCELLI MA, LANCE ET, DAMARAJU L, WAGNER CL, VVEISMAN HF, JORDAN RE: Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation (1998) 97:1680–1688.
   PubMed Web of Science ®Google Scholar
• TCHENG JE, ELLIS SG, GEORGE BS et al: Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation (1994) 90: 1757-1764.
   Google Scholar
• HARRINGTON RA, KLEIMAN NS, KOTTKE-MARCHANT K et al.: Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am. J. Cardiol (1995) 76:1222–1227.
   PubMed Web of Science ®Google Scholar
• KEREIAKES DJ, KLEIMAN NS, AMBROSE J et al.: Randomized, double-blind, placebo-controlled dose ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J. Am. Coll. Cardiol (1996) 27:536–542.
   PubMed Web of Science ®Google Scholar
• TAM SH, SASSOLI PM, JORDAN RE, NAKADA MT: Abciximab (ReoPro, Chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and aj33 integrins. Circulation (1998) 98:1085–1091.
   PubMed Web of Science ®Google Scholar
• SIMON DI, XU H, ORTLEPP S, ROGERS C, RAO NK: 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscier. a/MA V3SC. Biol. (1997) 17:528–535.
   PubMed Web of Science ®Google Scholar
• FAULDS D, SORKIN EM: Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease. Drugs (1994) 48:583–598.
   Google Scholar
• TCHENG JE, KEREIAKES DJ, LINC OFF AM et al.: Abciximab readministration: results of the ReoPro Readministration Registry. Circulation (2001) 104:870–875.
   Google Scholar
• THE PRISM STUDY INVESTIGATORS: A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl. J. Med. (1998) 338:1498–1505.
   PubMed Web of Science ®Google Scholar
• PRISM-PLUS STUDY INVESTIGATORS: Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl. J. Med. (1998) 338:1488–1497.
   PubMed Web of Science ®Google Scholar
• THE PURSUIT TRIAL INVESTIGATORS: Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl. J. Med. (1998) 339:436–443.
   PubMed Web of Science ®Google Scholar
• ••Large real-world trial of the GP IIb/IIIainhibitors.
   Google Scholar
• THE IMPACT-II INVESTIGATORS: Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet (1997) 349:1422–1428.
   PubMed Web of Science ®Google Scholar
• BEDNAR B, COOK JJ, HOLAHAN MAet al.: Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/IIIa. Blood (1999) 94:587–599.
   Google Scholar
• THE CAPTURE INVESTIGATORS: Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet (1997) 349:1429–1435.
   PubMed Web of Science ®Google Scholar
• THE GUSTO IV-ACS INVESTIGATORS: Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS RANDOMISED TRIAL: Lancet (2001) 357: 1915-1924.
   Google Scholar
• KEREIAKES DJ, BRODERICK TM, ROTH EM et al.: Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention. Am. J. Cardiol (1999) 84:391–395.
   PubMed Web of Science ®Google Scholar
• COHEN M, FERGUSON III JJ, HARRINGTON RA: Trials of glycoprotein IIb-IIIa inhibitors in non-ST-segment elevation acute coronary syndromes: applicability to the practice of medicine in the United States. Clin. Cardiol (1999) 22(Suppl. VI):VI2–V112.
   Google Scholar
• HARRINGTON RA, LINCOFF AM, BERDAN LG et al: Maintenance of clinical benefit at six-months in patients treated with platelet glycoprotein IIb/IIIa inhibitor eptifibatide versus placebo during an acute ischemic coronary event. Circulation (1998) 98(Suppl.):1-359 (Abstract).
   Google Scholar
• FINTEL DJ, LEDLEY GS: Management of patients with non-ST-segment elevation acute coronary syndromes. Clin. Cardiol (2000) 23(Suppl. V):V1–V12.
   Google Scholar
• MCCLURE MW, BERKOWITZ SD, SPARAPANI R et al.: Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial experience. Circulation (1999) 99:2892–2900.
   Google Scholar
• CANNON CP, WEINTRAUB WS, DEMOPOULOS LA et al: Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIB/IIIA inhibitor tirofiban. N Engl. J. Med. (2001) 344:1879–1887.
   PubMed Web of Science ®Google Scholar
• QUINN MJ, FITZGERALD DJ: Ticlopidine and clopidogrel. Circulation (1999) 100:1667–1672.
   PubMed Web of Science ®Google Scholar
• THE CLOPIDOGREL IN UNSTABLE ANGINA TO PREVENT RECURRENT EVENTS TRIAL INVESTIGATORS: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl. J. Med. (2001) 345:494–502.
   PubMed Web of Science ®Google Scholar
• ••Pivotol trial of the ADP receptor blocker.
   Google Scholar
• MEHTA SR, YUSUF S, PETERS RJG et al.: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet (2001) 358:527–533.
   PubMed Web of Science ®Google Scholar
• •Evaluates clopidogrel in the interventional setting.
   Google Scholar
• LINCOFF MA, BITTL JA et al: Bivalirudin and Provisional Glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE #2 Randomized Trial. JAMA (2003) 289:853–863.
   PubMed Web of Science ®Google Scholar
• •Recent trial comparing a direct thrombin inhibitor to the GP IIb/IIIa agents.
   Google Scholar
• SARICH TC, WOLZT M, ERIKSSON UG et al: Effects of Ximelagatran, an oral direct thrombin inhibitor, r-Hirudin and enoxaparin on thrombin generaton and platelet activation in healthy male subjects. JAM Coll. Cardiol (2003) 41:557–564.
   PubMed Web of Science ®Google Scholar
• •Early information on the oral direct thrombin inhibitor.
   Google Scholar
• TURPIE AGG, ERIKSSON BI, LASSEN MR, BAUER KA: Fondaparinux, the first selective Factor Xa inhibitor. Curr. Opin. Hematol (2003) 10:327–332.
   PubMed Web of Science ®Google Scholar
• •Concise review of fondaparinux.
   Google Scholar
• SIMMOONS M: Oral presentation on the PENTUA clinical trial. 74th Annual Scientific Sessions of the American Heart Association, Anaheim, CA, USA (2001).
   Google Scholar
• COUSSEMEN PK, BASSAND J-P, CONVENS C et al.: A synthetic Factor Xa inhibitor (ORG31540/sr90107a) as an adjunct fibrinolysis in acute myocardial infraction. The PENTALYSE study. Eui: Heart J. (2001) 22:1716–1724.
   Google Scholar
• •Comparison of Factor Xa inhibition to enoxaparin.
   Google Scholar
• SHIMBO D, OSENDE J, CHEN Jet al.: Antithrombotic effects of DX-9065a, a direct Factor Xa inhibitor. Thromb. Haemost. (2002) 88:733–738.
   Google Scholar
• •Evaluates Factor Xa inhibition in the setting of fibrinolysis.
   Google Scholar